Evidence map›Paper›PMID 39839540›Full record

ArticleOrganic process research & development2025

Characterization of Amorphous Ibrutinib Thermal Stability.

Dan Trunov, Jan Ižovský, Josef Beranek, Ondřej Dammer, Miroslav Šoóš

Abstract read
In one paragraph

Article in Organic process research & development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. ACS omega · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dan TrunovDepartment of Chemical Engineering, University of Chemistry and Technology, Technická 3, Prague 6, Dejvice 166 28, Czech Republic.ORCID https://orcid.org/0000-0002-6788-4985
Jan IžovskýDepartment of Chemical Engineering, University of Chemistry and Technology, Technická 3, Prague 6, Dejvice 166 28, Czech Republic.
Josef BeranekZentiva, k.s., U Kabelovny 130, Prague 10 102 00, Czech Republic.
Ondřej DammerZentiva, k.s., U Kabelovny 130, Prague 10 102 00, Czech Republic.
Miroslav ŠoóšDepartment of Chemical Engineering, University of Chemistry and Technology, Technická 3, Prague 6, Dejvice 166 28, Czech Republic.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The choice of method for drug amorphization depends on various factors, including the physicochemical properties of the active pharmaceutical ingredients, the desired formulation, and scalability requirements. It is often important to consider a combination of methods or the use of excipients to further enhance the stability and performance of the amorphous drug. This study presents a comparison of techniques including melt quench, hot melt extrusion, solvent evaporation, ball milling, and lyophilization used for the preparation of amorphous ibrutinib. The amorphous material was thoroughly investigated using numerous techniques to examine changes in the physicochemical properties, stability, and degradation pathways of the drug product. During the examination, the temperature was discovered to be a key parameter for controlling the solubility and permeability of ibrutinib, which is influenced by the presence of the degradation product. We found that this degradation product could potentially polymerize and increase the molecular weight. The quantity, polymerization rate, and structure of the impurity can be regulated by the temperature variation during the amorphization processes. Additionally, the molecular weight of the degradation product was determined using Zimm plot analysis, which appeared for the first time in the literature for molecules of this category.

Identifiers

PMID39839540
PMCPMC11744788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.